文献速递皮肤肿瘤

转移性黑色素瘤患者中lifileucel/白介素2相关皮疹

Cutaneous Eruptions and Lifileucel/Interleukin 2 in Individuals With Metastatic Melanoma.
PubMed 文献 · JAMA Dermatol · 2026-01-01

这项回顾性队列研究纳入44例接受lifileucel治疗的转移性黑色素瘤患者,22例(50.0%)在住院期间出现相关皮疹,中位出现时间为TIL输注后4天。皮疹与42天客观缓解相关(校正后OR 9.73,95%CI 2.12-44.74,P=.003),90天缓解分析未达统计学显著。

要点

  • lifileucel治疗后约半数患者出现皮疹,多为紫癜性斑丘疹。
  • 皮疹出现与42天影像学缓解显著相关,或为早期疗效标志。
  • 住院期间即可评估皮疹,早于传统42天再分期。

核心结论

  • lifileucel治疗常并发紫癜性斑丘疹,皮疹出现与短期影像学缓解相关,可能为围治疗期疗效标志。

研究设计与样本

  • Mass General Brigham/Dana-Farber癌症研究所的回顾性队列研究,纳入44例临床试验外接受lifileucel治疗的转移性黑色素瘤患者。
  • 所有患者接受环磷酰胺/氟达拉滨淋巴清除、lifileucel及≤6次IL-2输注,分析完成于2025年12月。

主要发现

  • 44例患者中22例(50.0%)在住院期间出现相关皮疹,中位出现时间为TIL输注后4天。
  • 22例中14例(63.6%)有可用照片,显示以中心分布为主的紫癜性斑丘疹。
  • 高IL-2组(4-6次)与低IL-2组(1-3次)的ORR无显著差异(50.0% vs 37.5%,P=.53)。
  • 皮疹出现与42天缓解相关:未校正OR 7.29(95%CI 1.91-27.86,P=.004);校正模型OR 9.73(95%CI 2.12-44.74,P=.003)。
  • 90天皮疹缓解分析均未检测到统计学显著性。

临床怎么用

  • 接受lifileucel治疗的患者住院期间应监测皮疹,出现紫癜性斑丘疹可能提示短期疗效较好。
  • 皮疹评估可在传统42天再分期前提供早期疗效线索。

局限性

  • 回顾性单中心队列,样本量44例,部分皮疹照片缺失。
  • 90天缓解分析未显示显著性,长期预后意义不确定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Lifileucel is a first-in-class autologous tumor-infiltrating lymphocyte (TIL) therapy for advanced/metastatic melanoma with progression after anti-programmed cell death protein 1 (PD-1) therapy and/or BRAF inhibitor therapy, if BRAF V600 mutations are present. In the C-144-01 phase 2 trial of lymphodepleting chemotherapy, lifileucel, and interleukin 2 (IL-2), cutaneous eruption occurred in 37.2% of individuals. These eruptions remain clinically and prognostically unknown. OBJECTIVE: To examine cutaneous toxic effects development in the setting of lifileucel therapy, abstract clinical and histopathologic eruption features, and test for association with objective radiographic tumor response. DESIGN, SETTING, AND PARTICIPANTS: A retrospective cohort study was performed at Mass General Brigham (MGB)/Dana-Farber Cancer Institute (DFCI) that included all patients treated with lifileucel, outside of active clinical trials. The analysis was completed in December 2025. EXPOSURES: All individuals received cyclophosphamide/fludarabine lymphodepletion, lifileucel, and 6 or fewer IL-2 infusions. Demographics, melanoma-specific factors (M stage, pre-TIL lactate dehydrogenase levels, and number of lines of prior systemic therapy), number of IL-2 doses received, eruption features, photography, and dermatopathologic findings were abstracted. MAIN OUTCOMES AND MEASURES: Radiographic responses 30 to 41 days, 42 to 89 days, and 90 days or longer from TIL infusion per Response Evaluation Criteria in Solid Tumors (RECIST) were abstracted. Individuals were stratified as high IL-2 (4-6 doses) or low IL-2 (1-3 doses), for objective response rate (ORR) comparison as a descriptive sensitivity analysis. An unadjusted logistic regression modeled tumor response as a binary outcome with lifileucel-associated eruption occurrence as a binary predictor. Three adjusted models included IL-2 doses (age, sex, and demographic differences) and melanoma-specific factors as covariates. RESULTS: Per retrospective electronic medical health record review, among 44 individuals (34.1% female individuals; mean [SD] age, 54.8 [14.5] years), treated with lifileucel (median, 4.5 IL-2 doses), 22 (50.0%) developed an associated cutaneous eruption while hospitalized, after a median of 4 post-TIL days. Photographs from 14 of 22 individuals (63.6%) with available images demonstrated central-predominant, frequently purpuric morbilliform eruptions. ORRs did not significantly differ by IL-2 stratification (high IL-2: 50.0% vs low IL-2: 37.5%; P = .53). Cutaneous eruption development was associated with a 42-day response across analyses (analysis 1: OR, 7.29; 95% CI, 1.91-27.86; P = .004; OR, 7.65; 95% CI, 1.79-32.69; P = .006; analysis 2: OR, 11.95; 95% CI, 1.90-75.39; P = .008; analysis 3: OR, 9.73; 95% CI, 2.12-44.74; P = .003); 30-day responses were statistically similarly associated. All 90-day cutaneous eruption response analyses did not detect statistical significance. CONCLUSIONS AND RELEVANCE: In this cohort study, lifileucel treatment was frequently complicated by purpuric morbilliform eruptions, which were prognostically favorable and associated with short-term response. The lifileucel-associated eruption may be a peritreatment efficacy marker, assessable during the TIL treatment hospitalization prior to traditional 42-day restaging.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Said JT, Li Y, Sadeghi N, et al. Cutaneous Eruptions and Lifileucel/Interleukin 2 in Individuals With Metastatic Melanoma. JAMA Dermatol. 2026. PMID: 41984455. doi:10.1001/jamadermatol.2026.0605

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。